Fiduciary Family Office LLC Buys Shares of 5,456 IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Fiduciary Family Office LLC acquired a new stake in IQVIA Holdings Inc., purchasing 5,456 shares valued at approximately $962,000.
• Analysts have provided mixed reviews on IQVIA, with recent price targets ranging from $160.00 to $235.00, and a consensus rating of "Moderate Buy."
• IQVIA reported earnings of $2.81 EPS for the last quarter, exceeding analysts' estimates, with total revenue of $4.02 billion, marking a 5.3% increase year-over-year.

Fiduciary Family Office LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,456 shares of the medical research company's stock, valued at approximately $962,000.

A number of other large investors have also recently made changes to their positions in IQV. American National Bank & Trust bought a new stake in IQVIA during the first quarter valued at approximately $26,000. Golden State Wealth Management LLC increased its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA in the first quarter worth about $33,000. ST Germain D J Co. Inc. grew its holdings in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. bought a new position in IQVIA during the 4th quarter worth about $39,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on IQV. UBS Group increased their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Barclays lifted their price target on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Redburn Partners set a $188.00 price objective on IQVIA in a report on Friday, May 23rd. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Trading Up 0.2%

NYSE IQV traded up $0.32 during mid-day trading on Monday, hitting $180.18. The company's stock had a trading volume of 1,071,033 shares, compared to its average volume of 2,386,483. The firm has a market capitalization of $30.63 billion, a P/E ratio of 26.07, a price-to-earnings-growth ratio of 1.97 and a beta of 1.30. The stock's fifty day simple moving average is $167.06 and its two-hundred day simple moving average is $168.77. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the company earned $2.64 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.